Horizon Discovery: CRISPR Modulation Reagents

Horizon Discovery, a PerkinElmer company, has launched a new family of CRISPR modulation reagents for CRISPR interference, enabling researchers a better understanding of the biological pathways, processes, and pathologies of disease by repressing genes at the transcription level, and leading to new therapies.

The new reagents include what Horizon Discovery said are the first commercially available synthetic single guide RNAs for CRISPRi. Also included is a dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. The new technologies gives researchers the ability to repress genes in almost all cell lines, across any length of time, and at any scale, Horizon Discovery said.